Granules India Limited receives final approval from USFDA for its new drug
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Granules India gets USFDA’s nod for ADHD generic
Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...
VOCM News20h
ADHD Diagnosis Tied to Reduced Lifespan, Study Finds
Mortality data collected by researchers showed that life expectancy was reduced in diagnosed adults by close to 7 years in men and more than 8 years in women. The research paper released this month ...